 Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively Agios to Host Live and Webcast Investor Event on Dec. 12, 2022, at 7 a.m. CT CAMBRIDGE, Mass., Dec. 10, 2022 GLOBE NEWSWIRE Agios Pharmaceuticals, Inc. NASDAQ: AGIO, a leader in ... The post Agios Presents Updated PYRUKYND mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in... 